چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده | نفر چندم مقاله |
|---|---|
| سید امین سیدرضایی | اول |
| معین کوهکلانی | دوم |
| محمد اصغرزاده | سوم |
| وحید اصغرزاده | چهارم |
| عنوان | متن |
|---|---|
| کلمات کلیدی | Breast Cancer, microRNA, miRNA, prognosis |
| خلاصه مقاله | Introduction Breast cancer remains a major public health challenge, accounting for significant morbidity and mortality worldwide. Advances in molecular biology have identified microRNAs (miRNAs), a class of small non-coding RNAs, as key regulators of gene expression with critical roles in carcinogenesis, tumor progression, and therapeutic resistance. Their distinct expression patterns in breast cancer patients have positioned miRNAs as potential biomarkers for diagnosis, prognosis, and treatment monitoring. This review synthesizes current knowledge of miRNA roles in breast cancer, focusing on their potential as biomarkers and their clinical implications for diagnosis, prognosis, and therapeutic resistance. Methods This review analyzes 300 published articles from January 2017 to December 2023, of which 12 were selected based on relevance and quality. Articles were identified using the keywords miRNA, breast cancer, diagnosis, prognosis, and therapeutic resistance and evaluated to summarize current knowledge of miRNA expression patterns and their implications for breast cancer diagnosis, prognosis, and treatment. Results Dysregulation of miRNAs is a hallmark of breast cancer, with distinct patterns of upregulation and downregulation observed in patient samples. MiRNA-205, a tumor suppressor, is frequently downregulated in aggressive and metastatic breast cancer subtypes. Its reduced expression is associated with poor prognosis, higher tumor grade, and therapy resistance. Functionally, miRNA-205 inhibits epithelial-to-mesenchymal transition (EMT) by targeting key transcriptional repressors such as zinc finger E-box-binding homeobox 1 (ZEB1) and ZEB2, thereby reducing tumor invasiveness and metastatic potential. Additionally, it modulates pathways like PI3K/AKT and MAPK, suppressing proliferation and promoting apoptosis. Given its consistent downregulation, miRNA-205 serves as a promising diagnostic and prognostic biomarker. Preclinical studies show that restoring miRNA-205 expression using mimics or nanocarriers can re-establish its tumor-suppressive functions, underscoring its therapeutic potential. In addition to miR-205, miR-200c and miR-141, both implicated in breast cancer pathogenesis, show decreased expression levels in breast cancer patients compared to healthy individuals. Notably, miR-200c levels are elevated in stage 4 patients with low MIB-1 expression, while miR-141 expression is significantly increased in earlier stages (1–3), as well as in cases of lymph node metastases and HER2-negative tumors. These findings suggest that miR-141 and miR-200c may serve as prognostic indicators, with their altered expression profiles linked to disease progression and patient outcomes. Additionally, miR-10 b and miR-373 are markedly upregulated in the serum of patients with lymph node metastases, making them valuable biomarkers for assessing lymphatic involvement. In addition to their diagnostic and prognostic roles, miRNAs contribute to therapeutic resistance. For example, miR-29a and miR-222 have been shown to modulate breast cancer cell resistance to adriamycin and docetaxel, respectively. These findings underscore the multifaceted roles of miRNAs in breast cancer, spanning tumor biology and treatment response. Conclusion MicroRNAs hold significant promise as biomarkers for the diagnosis, prognosis, and therapeutic management of breast cancer. Their ability to predict and influence drug resistance further highlights their clinical relevance. By integrating miRNA profiling into breast cancer research and clinical practice, we can improve early detection, personalize treatment strategies, and enhance patient outcomes. |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| BCcongress.pdf | 1404/02/12 | 102775 | دانلود |
| 20250425_134138.jpg | 1404/02/12 | 1602133 | دانلود |
| LD2025.pptx | 1404/02/12 | 3355607 | دانلود |
